Clinical trial Recruiting at 1 site Observational Ages 60 and up

Frailty plus Nottingham Hip Fracture Score to predict 90-day death risk after hip surgery

Official title: Incremental Prognostic Value of Frailty Beyond the Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture Surgery: A Prospective Cohort Study

Run by Trakya University · NCT07481188 · Data updated 2026-11-12

This project will test whether adding a quick frailty check (Clinical Frailty Scale) to the Nottingham Hip Fracture Score helps doctors better predict 90-day death risk for people aged 60 and older having hip fracture surgery.

More Frailty trials

Quick facts

Study typeObservational
Ages60 Years and up
SexAll
Enrollment200 (estimated)
SponsorTrakya University
Academic / other
Locations1 site (Edirne)
StatusRecruiting
StartedMarch 15, 2026
Main results expectedMarch 15, 2027
Study endsMarch 15, 2027
Registry record updatedMarch 31, 2026
Trial IDNCT07481188 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 60 or older admitted for acute proximal femoral fracture (femoral neck, intertrochanteric, or subtrochanteric) who undergo surgical fixation and for whom NHFS and pre-fracture frailty data can be obtained.

Probably not a fit

Patients with pathological or periprosthetic fractures, high-energy/polytrauma, those managed non-operatively, or second hip fractures in the same patient during the study period are excluded and would not be expected to benefit from these prediction results.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational cohort of patients aged 60 and older admitted with acute proximal femoral fractures who undergo surgical treatment at Trakya University. Investigators will record routine clinical data used to calculate the Nottingham Hip Fracture Score (NHFS) and measure pre-fracture frailty using the Clinical Frailty Scale (CFS). The study will compare how well the NHFS alone versus NHFS plus CFS predicts 90-day mortality using standard prediction metrics such as discrimination and calibration. No experimental treatments are given; care is per usual clinical practice and data are analyzed retrospectively or prospectively depending on enrollment.

Why it matters

Potential benefit: If successful, combining frailty assessment with the NHFS could help clinicians more accurately identify patients at high risk of death within 90 days and tailor perioperative planning and post-discharge support.

How similar studies have gone: Previous research has validated the NHFS for short-term mortality and shown frailty independently predicts worse post‑fracture outcomes, and combining frailty measures with risk scores has shown promise though this exact NHFS+CFS combination for 90-day mortality is less well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 60 years or older
* Admission for acute proximal femoral fracture (femoral neck, intertrochanteric, or subtrochanteric fracture)
* Surgical treatment for hip fracture
* Ability to obtain clinical data required for NHFS and frailty assessment

Exclusion Criteria:

* Pathological fractures
* Periprosthetic fractures
* Hip fractures resulting from high-energy trauma or polytrauma
* Non-operative treatment
* Second hip fracture occurring in the same patient during the study period

Where it's running

  • Trakya University
    Edirne, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.